CA3012466A1 - Use of cd24 proteins for treating leptin-deficient conditions - Google Patents

Use of cd24 proteins for treating leptin-deficient conditions Download PDF

Info

Publication number
CA3012466A1
CA3012466A1 CA3012466A CA3012466A CA3012466A1 CA 3012466 A1 CA3012466 A1 CA 3012466A1 CA 3012466 A CA3012466 A CA 3012466A CA 3012466 A CA3012466 A CA 3012466A CA 3012466 A1 CA3012466 A1 CA 3012466A1
Authority
CA
Canada
Prior art keywords
protein
subject
day
mins
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA3012466A
Other languages
English (en)
French (fr)
Inventor
Yang Liu
Pan Zheng
Martin DEVENPORT
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncoimmune Inc
Original Assignee
Oncoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncoimmune Inc filed Critical Oncoimmune Inc
Publication of CA3012466A1 publication Critical patent/CA3012466A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CA3012466A 2016-02-02 2017-02-02 Use of cd24 proteins for treating leptin-deficient conditions Abandoned CA3012466A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662290202P 2016-02-02 2016-02-02
US62/290,202 2016-02-02
PCT/US2017/016120 WO2017136492A1 (en) 2016-02-02 2017-02-02 Use of cd24 proteins for treating leptin-deficient conditions

Publications (1)

Publication Number Publication Date
CA3012466A1 true CA3012466A1 (en) 2017-08-10

Family

ID=59500202

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3012466A Abandoned CA3012466A1 (en) 2016-02-02 2017-02-02 Use of cd24 proteins for treating leptin-deficient conditions

Country Status (8)

Country Link
US (2) US10799558B2 (enExample)
EP (1) EP3411062B1 (enExample)
JP (1) JP6938835B2 (enExample)
KR (1) KR20180120145A (enExample)
CN (1) CN109069583B (enExample)
CA (1) CA3012466A1 (enExample)
SG (1) SG11201806338SA (enExample)
WO (1) WO2017136492A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217659A1 (en) * 2017-05-22 2018-11-29 Oncoimmune, Inc. Methods of use of soluble cd24 for treating immune related adverse events in cancer therapies
SG11202007815TA (en) * 2018-03-05 2020-09-29 Oncoimmune Inc Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
WO2019236474A1 (en) 2018-06-04 2019-12-12 Oncoimmune, Inc. Methods of use of cd24 for the prevention and treatment of leukemia relapse
US20220000974A1 (en) * 2019-02-06 2022-01-06 Oncolmmune, Inc. Targeting CD24-Siglec Interactions for Treating Subjects with Prediabetes or Diabetes
WO2020163529A1 (en) * 2019-02-06 2020-08-13 Oncoimmune, Inc. Targeting cd24-siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001259792B2 (en) * 2000-03-29 2005-12-22 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive T cells
WO2004106495A2 (en) * 2003-05-29 2004-12-09 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
JP5899206B2 (ja) * 2010-04-28 2016-04-06 オンコイミューン， インコーポレイテッド 関節リウマチの治療のための可溶性ｃｄ２４の使用方法
JP6116568B2 (ja) 2011-08-30 2017-04-19 アカデミッシュ メディッシュ セントラム インスリン抵抗性を予防および／または処置する方法
HK1214628A1 (zh) * 2012-11-05 2016-07-29 Pronai Therapeutics, Inc. 寡核苷酸癌症療法的給藥和施用

Also Published As

Publication number Publication date
CN109069583B (zh) 2021-09-21
KR20180120145A (ko) 2018-11-05
EP3411062B1 (en) 2020-11-25
JP2019506408A (ja) 2019-03-07
WO2017136492A1 (en) 2017-08-10
US20190038716A1 (en) 2019-02-07
JP6938835B2 (ja) 2021-09-22
US10799558B2 (en) 2020-10-13
EP3411062A1 (en) 2018-12-12
EP3411062A4 (en) 2019-09-25
US20210162006A1 (en) 2021-06-03
SG11201806338SA (en) 2018-08-30
CN109069583A (zh) 2018-12-21

Similar Documents

Publication Publication Date Title
US20210162006A1 (en) Use of CD24 Proteins for Treating Leptin-Deficient Conditions
US20250282843A1 (en) Compositions comprising an interleukin construct
US11026995B2 (en) Use of CD24 for lowering low-density lipoprotein cholesterol levels
EP2970422B1 (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
EP2948161B1 (en) Follistatin in treating duchenne muscular dystrophy
TW201709927A (zh) 使用ＡＣＴＲＩＩ配位體捕捉以治療β－地中海型貧血
CA2891386A1 (en) Compositions and methods for the treatment of ectodermal dysplasia
HK40002090B (zh) 使用cd24蛋白治疗瘦素缺乏病状
KR20190126801A (ko) 전신 홍반성 루푸스를 치료하기 위한 가용성 cd24의 사용 방법
HK40002090A (en) Use of cd24 proteins for treating leptin-deficient conditions
US20220000973A1 (en) Targeting CD24-Siglec Interactions for the Treatment and Prevention of Nonalcoholic Steatohepatitis
WO2020163523A2 (en) Targeting cd24-siglec interactions for treating subjects with prediabetes or diabetes
HK1217637B (en) Follistatin in treating duchenne muscular dystrophy

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210318

EEER Examination request

Effective date: 20210318

FZDE Discontinued

Effective date: 20230704